التفاصيل البيبلوغرافية
| العنوان: |
Changing the landscape for type 1 diabetes: the first step to prevention. |
| المؤلفون: |
Dayan, Colin M1 (AUTHOR), Korah, Maria2 (AUTHOR), Tatovic, Danijela2 (AUTHOR), Bundy, Brian N3 (AUTHOR), Herold, Kevan C1,2 (AUTHOR) kevan.herold@yale.edu |
| المصدر: |
Lancet. Oct2019, Vol. 394 Issue 10205, p1286-1296. 11p. |
| مصطلحات موضوعية: |
TYPE 1 diabetes, LANDSCAPE changes, DIAGNOSIS, MONOCLONAL antibodies, ADULT-child relationships, THERAPEUTIC use of monoclonal antibodies |
| مستخلص: |
Over several decades, studies have described the progression of autoimmune diabetes, from the first appearance of autoantibodies until, and after, the diagnosis of clinical disease with hyperglycaemia and insulin dependence. Despite the improved management of type 1 diabetes with exogenous insulin, most patients do not meet clinical glycaemic goals, and diabetes remains an important medical problem that affects children and adults. Clinical and preclinical studies have suggested strategies to prevent the diagnosis of type 1 diabetes in people at risk, but the outcomes of previous clinical trials have not met their primary endpoints of disease prevention or delay. The results from the TN-10 teplizumab prevention trial show that the diagnosis of type 1 diabetes can be delayed by treatment with a FcR non-binding monoclonal antibody to CD3 in people at high risk for disease. This Series paper discusses how this clinical achievement raises new questions about for whom, and when, immunological strategies might be developed to prevent type 1 diabetes, and how to achieve this goal. [ABSTRACT FROM AUTHOR] |
|
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Business Source Index |
